@article{The_OpenSAFELY_Collaborative-2022_111561,
title = {Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients on kidney replacement therapy: observational cohort study using the OpenSAFELY-UKRR linked platform and SRR database [pre-print]},
author = {The OpenSAFELY Collaborative and Zheng, B. and Campbell, J. and Carr, E. and Tazare, J. and Nab, L. and Mahalingasivam, V. and Mehrkar, A. and Santhakumaran, S. and Steenkamp, R. and Loud, F. and Lyon, S. and Scanlon, M. and Hulme, W. and Green, A. and Curtis, H. and Fisher, L. and Parker, E. and Goldacre, B. and Douglas, I. and Evans, S. and Mackenna, B. and Bell, S. and Tomlinson, L. and Nitsch, D. and LH&W NCS (or CONVALESCENCE) Collaborative},
month = {dec},
year = {2022},
abstract = {BackgroundPatients on kidney replacement therapy (KRT; dialysis and kidney transplantation) are at the highest risk of severe outcomes from COVID-19. Due to limited inclusion of patients on KRT in clinical trials, information is limited on the effectiveness of sotrovimab (a neutralising monoclonal antibody). We sought to address this by comparing its effectiveness against molnupiravir (an antiviral) in preventing severe COVID-19 outcomes in non-hospitalised adults with symptomatic COVID-19.},
journal = {medRxiv},
publisher = {medRxiv},
url = {https://doi.org/10.1101/2022.12.02.22283049},
}
